Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra
Abstract
:1. Introduction
2. Description and Function of Mast Cells (MCs)
3. Relationship between Mast Cells and Proinflammatory and Anti-Inflammatory Cytokines in Inflammation
4. IL-33 Is a Proinflammatory Cytokine
5. Intervention of IL-1 in Psoriatic Inflammation
6. IL-1 Receptor Antagonist in Psoriasis
7. IL-38: The New Cytokine That Inhibits Inflammation
8. Suppression of Inflammation Due to IL-37
Author Contributions
Funding
Conflicts of Interest
References
- Theoharides, T.C.; Zhang, B.; Kempuraj, D.; Tagen, M.; Vasiadi, M.; Angelidou, A.; Alysandratos, K.D.; Kalogeromitros, D.; Asadi, S.; Stavrianeas, N.; et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. USA 2010, 107, 4448–4453. [Google Scholar] [CrossRef] [Green Version]
- Ritchlin, C.T.; Colbert, R.A.; Gladman, D.D. Psoriatic arthritis. N. Engl. J. Med. 2017, 376, 957–9700. [Google Scholar] [CrossRef] [Green Version]
- Gudjonsson, J.E.; Johnston, A.; Dyson, M.; Valdimarsson, H.; Elder, J.T. Mouse models of psoriasis. J. Investig. Dermatol. 2007, 127, 1292–1308. [Google Scholar] [CrossRef] [Green Version]
- Nestle, F.O.; Kaplan, D.H.; Barker, J. Psoriasis. N. Engl. J Med. 2009, 361, 496–509. [Google Scholar] [CrossRef]
- Kempuraj, D.; Conti, P.; Vasiadi, M.; Alysandratos, K.D.; Tagen, M.; Kalogeromitros, D.; Kourelis, T.; Gregoriou, S.; Makris, M.; Stavrianeas, N.G.; et al. IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. Eur. J. Dermatol. 2010, 20, 865–867. [Google Scholar]
- Van de Kerkhof, P.C.; Gerritsen, M.J.; de Jong, E.M. Transition from symptomless to lesional psoriatic skin. Clin. Exp. Dermatol. 1996, 21, 325–329. [Google Scholar] [CrossRef]
- Konnikov, N.; Pincus, S.H.; Dinarello, C.A. Elevated plasma interleukin-1 levels in humans following ultraviolet light therapy for psoriasis. J. Investig. Dermatol. 1989, 92, 235–239. [Google Scholar] [CrossRef] [Green Version]
- Kritas, S.K.; Saggini, A.; Varvara, G.; Murmura, G.; Caraffa, A.; Antinolfi, P.; Toniato, E.; Pantalone, A.; Neri, G.; Frydas, S.; et al. Impact of mast cells on the skin. Int. J. Immunopathol. Pharmacol. 2013, 26, 855–859. [Google Scholar] [CrossRef] [PubMed]
- Teunissen, M.B.; Zheng, L.; de Groot, M.; de Rie, M.A.; Fine, J.S.; Chen, S.C. Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions. Arch. Dermatol. Res. 2012, 304, 443–449. [Google Scholar] [CrossRef] [Green Version]
- Boehncke, W.H.; Brembilla, N.C. Unmet needs in the field of psoriasis: Pathogenesis and treatment. Clin. Rev. Allergy Immunol. 2018, 55, 295–311. [Google Scholar] [CrossRef]
- Clavel, G.; Thiolat, A.; Boissier, M.C. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine 2013, 80, 449–453. [Google Scholar] [CrossRef]
- Albanesi, C.; Madonna, S.; Gisondi, P.; Girolomoni, G. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front. Immunol. 2018, 9, 1549. [Google Scholar] [CrossRef] [Green Version]
- Hänsel, A.; Günther, C.; Ingwersen, J.; Starke, J.; Schmitz, M.; Bachmann, M.; Meurer, M.; Rieber, E.P.; Schäkel, K. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin. Immunol. 2011, 127, e1–e9. [Google Scholar] [CrossRef]
- Theoharides, T.C.; Donelan, J.M.; Papadopoulou, N.; Cao, J.; Kempuraj, D.; Conti, P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol. Sci. 2004, 25, 563–568. [Google Scholar] [CrossRef] [PubMed]
- Ma, H.L.; Napierata, L.; Stedman, N.; Benoit, S.; Collins, M.; Nickerson-Nutter, C.; Young, D.A. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010, 62, 430–440. [Google Scholar] [CrossRef]
- Fang, H.; Zhang, Y.; Li, N.; Wang, G.; Liu, Z. The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury. Front. Immunol. 2018, 9, 407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Galli, S.J.; Kalesnikoff, J.; Grimbaldeston, M.A.; Piliponsky, A.M.; Williams, C.M.; Tsai, M. Mast cells as “tunable” effector and immunoregulatory cells: Recent advances. Annu. Rev. Immunol. 2005, 23, 749–786. [Google Scholar] [CrossRef] [PubMed]
- Galli, S.J.; Tsai, M. Mast cells: Versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J. Dermatol. Sci. 2008, 49, 7–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Galli, S.J.; Borregaard, N.; Wynn, T.A. Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. Nat. Immunol. 2011, 12, 1035–1044. [Google Scholar] [CrossRef] [Green Version]
- Antonopoulos, D.; Tsilioni, I.; Balatsos, N.A.A.; Gourgoulianis, K.I.; Theoharides, T.C. The mast cell-Neurofibromatosis connection. J. Biol. Regul. Homeost. Agents 2019, 33, 657–659. [Google Scholar]
- Reber, L.L.; Hernandez, J.D.; Galli, S.J. The pathophysiology of anaphylaxis. J. Allergy Clin. Immunol. 2017, 140, 335–348. [Google Scholar] [CrossRef] [Green Version]
- Taracanova, A.; Tsilioni, I.; Conti, P.; Norwitz, E.R.; Leeman, S.E.; Theoharides, T.C. Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin. Proc. Natl. Acad. Sci. USA 2018, 115, E9381–E9390. [Google Scholar] [CrossRef] [Green Version]
- Caraffa, A.l.; Gallenga, C.E.; Kritas, S.K.; Ronconi, G.; Conti, P. Impact of mast cells in systemic lupus erythematosus: Can inflammation be inhibited? J. Biol. Regul. Homeost. Agents 2019, 33, 669–673. [Google Scholar]
- Dinarello, C.A. Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity. Immunol. Rev. 2018, 281, 5–7. [Google Scholar] [CrossRef] [Green Version]
- Franza, L.; Carusi, V.; Altamura, S.; Caraffa, A.; Gallenga, C.E.; Kritas, S.K.; Ronconi, G.; Conti, P.; Pandolfi, F. Interrelationship between inflammatory cytokines (IL-1, IL-6, IL-33, IL-37) and acquired immunity. J. Biol. Regul. Homeost. Agents 2019, 33, 1321–1326. [Google Scholar]
- Taracanova, A.; Alevizos, M.; Karagkouni, A.; Weng, Z.; Weng, Z.; Norwitz, E.; Conti, P.; Leeman, S.E.; Theoharides, T.C. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc. Natl. Acad. Sci. USA 2017, 114, E4002–E4009. [Google Scholar] [CrossRef] [Green Version]
- Gallenga, C.E.; Pandolfi, F.; Caraffa, A.; Kritas, S.K.; Ronconi, G.; Toniato, E.; Martinotti, S.; Conti, P. Interleukin-1 family cytokines and mast cells: Activation and inhibition. J. Biol. Regul. Homeost. Agents 2019, 33, 1–6. [Google Scholar]
- Conti, P.; Gallenga, C.E.; Ronconi, G.; Caraffa, A.; Kritas, S.K. Activation of mast cells mediates inflammatory response in psoriasis: Potential new therapeutic approach with IL-37. Dermatol. Ther. 2019, 32, e12943. [Google Scholar] [CrossRef]
- Schottelius, A.J.; Moldawer, L.L.; Dinarello, C.A.; Asadullah, K.; Sterry, W.; Edwards, C.K., 3rd. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp. Dermatol. 2004, 13, 193–222. [Google Scholar] [CrossRef]
- Kalesnikoff, J.; Galli, S.J. Antiinflammatory and immunosuppressive functions of mast cells. Methods Mol. Biol. 2011, 677, 207–220. [Google Scholar]
- Garlanda, C.; Dinarello, C.A.; Mantovani, A. The interleukin-1 family: Back to the future. Immunity 2013, 39, 1003–1018. [Google Scholar] [CrossRef] [Green Version]
- Onuora, S. IL-36 inhibition to treat OA. Nat. Rev. Rheumatol. 2019, 15, 386. [Google Scholar] [CrossRef]
- Zimmermann, C.; Troeltzsch, D.; Giménez-Rivera, V.A.; Galli, S.J.; Metz, M.; Maurer, M.; Siebenhaar, F. Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. Proc. Natl. Acad. Sci. USA 2019, 116, 20500–20504. [Google Scholar] [CrossRef] [Green Version]
- van de Veerdonk, F.L.; Stoeckman, A.K.; Wu, G.; Boeckermann, A.N.; Azam, T.; Netea, M.G.; Joosten, L.A.; van der Meer, J.W.; Hao, R.; Kalabokis, V.; et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl. Acad. Sci. USA 2012, 109, 3001–3005. [Google Scholar] [CrossRef] [Green Version]
- Mantovani, A.; Dinarello, C.A.; Molgora, M.; Garlanda, C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 2019, 50, 778–795. [Google Scholar] [CrossRef] [Green Version]
- Nold, M.F.; Nold-Petry, C.A.; Zepp, J.A.; Palmer, B.E.; Bufler, P.; Dinarello, C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 2010, 11, 1014–1022. [Google Scholar] [CrossRef] [Green Version]
- van de Veerdonk, F.L.; de Graaf, D.M.; Joosten, L.A.; Dinarello, C.A. Biology of IL-38 and its role in disease. Immunol. Rev. 2018, 281, 191–196. [Google Scholar] [CrossRef]
- Dinarello, C.A. Overview of the interleukin-1 family of ligands and receptors. Semin. Immunol. 2013, 25, 389–393. [Google Scholar] [CrossRef] [PubMed]
- Boutet, M.A.; Nerviani, A.; Pitzalis, C. IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: A comprehensive review of their therapeutic potential. Int. J. Mol. Sci. 2019, 20, 1257. [Google Scholar] [CrossRef] [Green Version]
- Buhl, A.L.; Wenzel, J. Interleukin-36 in infectious and inflammatory skin diseases. Front. Immunol. 2019, 10, 1162. [Google Scholar] [CrossRef] [PubMed]
- Vigne, S.; Palmer, G.; Lamacchia, C.; Martin, P.; Talabot-Ayer, D.; Rodriguez, E.; Ronchi, F.; Sallusto, F.; Dinh, H.; Sims, J.E.; et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011, 118, 5813–5823. [Google Scholar] [CrossRef]
- Towne, J.E.; Sims, J.E. Il-36 in psoriasis. Curr. Opin. Pharmacol. 2012, 12, 486–490. [Google Scholar] [CrossRef]
- Müller, A.; Hennig, A.; Lorscheid, S.; Grondona, P.; Schulze-Osthoff, K.; Hailfinger, S.; Kramer, D. IκBζ is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes. Proc. Natl. Acad. Sci. USA 2018, 115, 10088–10093. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arakawa, A.; Ruzicka, T.; Prinz, J.C. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016, 152, 825–828. [Google Scholar] [CrossRef] [PubMed]
- Blumberg, H.; Dinh, H.; Trueblood, E.S.; Pretorius, J.; Kugler, D.; Weng, N.; Kanaly, S.T.; Towne, J.E.; Willis, C.R.; Kuechle, M.K.; et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 2007, 204, 2603–2614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carrier, Y.; Ma, H.L.; Ramon, H.E.; Napierata, L.; Small, C.; O'Toole, M.; Young, D.A.; Fouser, L.A.; Nickerson-Nutter, C.; Collins, M.; et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: Implications in psoriasis pathogenesis. J. Investig. Dermatol. 2011, 131, 2428–2437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Conti, P.; Caraffa, A.; Tetè, G.; Gallenga, C.E.; Ross, R.; Kritas, S.K.; Frydas, I.; Younes, A.; Di Emidio, P.; Ronconi, G. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J. Biol. Regul. Homeost. Agents 2020, 18, 34. [Google Scholar]
- Mo, X.J.; Ye, X.Z.; Li, Y.P. Effects of euphorbia kansui on the serum levels of IL-6, TNF-α, NF-κB, sTNFR and IL-8 in patients with severe acute pancreatitis. J. Biol. Regul. Homeost. Agents 2019, 33, 469–475. [Google Scholar]
- Su, X.M. Expressions, function and significance of IL-10 and RANTES in rats with allergic rhinitis. J. Biol. Regul. Homeost. Agents 2019, 33, 1227–1232. [Google Scholar]
- Conti, P.; Caraffa, A.; Ronconi, G.; Kritas, S.K.; Mastrangelo, F.; Tettamanti, L.; Theoharides, T.C. Impact of mast cells in mucosal immunity of intestinal inflammation: Inhibitory effect of IL-37. Eur. J. Pharmacol. 2018, 818, 294–299. [Google Scholar] [CrossRef]
- Conti, P.; Caraffa, A.; Gallenga, C.E.; Ross, R.; Kritas, S.K.; Frydas, I.; Younes, A.; Di Emidio, P.; Ronconi, G.; Toniato, E. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: Inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J. Biol. Regul. Homeost. Agents 2020, 3, 34. [Google Scholar]
- Waisman, A. To be 17 again-anti-interleukin-17 treatment for psoriasis. N. Engl. J. Med. 2012, 366, 1251–1252. [Google Scholar] [CrossRef] [PubMed]
- Dinarello, C.A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 2018, 281, 8–27. [Google Scholar] [CrossRef]
- Theoharides, T.C.; Petra, A.I.; Taracanova, A.; Panagiotidou, S.; Conti, P. Targeting IL-33 in autoimmunity and inflammation. J. Pharmacol. Exp. Ther. 2015, 354, 24–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cayrol, C.; Girard, J.P. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol. Rev. 2018, 281, 154–168. [Google Scholar] [CrossRef] [PubMed]
- Dinarello, C.A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 2007, 27, 98–114. [Google Scholar] [CrossRef]
- Dinarello, C.A.; Conti, P.; Mier, J.W. Effects of human interleukin-1 on natural killer cell activity: Is fever a host defense mechanism for tumor killing? Yale J. Biol. Med. 1986, 59, 97–106. [Google Scholar]
- Dinarello, C.; Arend, W.; Sims, J.; Smith, D.; Blumberg, H.; O'Neill, L.; Goldbach-Mansky, R.; Pizarro, T.; Hoffman, H.; Bufler, P.; et al. IL-1 family nomenclature. Nat. Immunol. 2010, 11, 973. [Google Scholar] [CrossRef] [Green Version]
- Theoharides, T.C.; Tsilioni, I.; Bawazeer, M. Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. Front. Cell Neurosci. 2019, 13, 353. [Google Scholar] [CrossRef]
- Serhan, N.; Basso, L.; Sibilano, R.; Petitfils, C.; Meixiong, J.; Bonnart, C.; Reber, L.L.; Marichal, T.; Starkl, P.; Cenac, N.; et al. House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation. Nat. Immunol. 2019, 20, 1435–1443. [Google Scholar] [CrossRef]
- Biasucci, L.M.; Liuzzo, G.; Fantuzzi, G.; Caligiuri, G.; Rebuzzi, A.G.; Ginnetti, F.; Dinarello, C.A.; Maseri, A. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999, 99, 2079–2084. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Banwell, V.; Sena, E.S.; Macleod, M.R. Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J. Stroke Cerebrovasc. Dis. 2009, 18, 269–276. [Google Scholar] [CrossRef] [PubMed]
- Banks, W.A.; Kastin, A.J.; Broadwell, R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2, 241–248. [Google Scholar] [CrossRef] [PubMed]
- Gabay, C.; Genin, B.; Mentha, G.; Iynedjian, P.B.; Roux-Lombard, P.; Guerne, P.A. IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells. Clin. Exp. Immunol. 1995, 100, 306–313. [Google Scholar] [CrossRef] [PubMed]
- Dinarello, C.A.; van der Meer, J.W. Treating inflammation by blocking interleukin-1 in humans. Semin. Immunol. 2013, 25, 469–484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kutukculer, N.; Puel, A.; Eren Akarcan, S.; Moriya, K.; Edeer Karaca, N.; Migaud, M.; Casanova, J.L.; Aksu, G. Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy. Case Rep. Immunol. 2019, 2019, 1902817. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Girolomoni, G.; Mrowietz, U.; Paul, C. Psoriasis: Rationale for targeting interleukin-17. Br. J. Dermatol. 2012, 167, 717–724. [Google Scholar] [CrossRef] [PubMed]
- Tsang, M.S.; Sun, X.; Wong, C.K. The Role of New IL-1 Family Members (IL-36 and IL-38) in Atopic Dermatitis, Allergic Asthma, and Allergic Rhinitis. Curr Allergy Asthma Rep. 2020, 20, 40. [Google Scholar] [CrossRef]
- Mercurio, L.; Morelli, M.; Scarponi, C.; Eisenmesser, E.Z.; Doti, N.; Pagnanelli, G.; Gubinelli, E.; Mazzanti, C.; Cavani, A.; Ruvo, M.; et al. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis. 2018, 9, 1104. [Google Scholar] [CrossRef]
- Madonna, S.; Girolomoni, G.; Dinarello, C.A.; Albanesi, C. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. Int. J. Mol. Sci. 2019, 20, 3318. [Google Scholar] [CrossRef] [Green Version]
- Papathanasiou, E.; Conti, P.; Carinci, F.; Lauritano, D.; Theoharides, T.C. IL-1 Superfamily Members and Periodontal Diseases. J. Dent. Res. 2020, 99, 1425–1434. [Google Scholar] [CrossRef]
- Dinarello, C.A. The IL-1 family of cytokines and receptors. Nat. Rev. Rheumatol. 2019, 15, 612–632. [Google Scholar] [CrossRef]
- Conti, P.; Gallenga, C.E.; Caraffa, A.; Ronconi, G.; Kritas, S.K. Impact of Mast cells in fibromyalgia and low-grade chronic inflammation: Can IL-37 play a role? Dermatol. Ther. 2019, 33, e13191. [Google Scholar] [CrossRef]
- Liu, T.; Liu, J.; Lin, Y.; Que, B.; Chang, C.; Zhang, J.; Liang, Z.; Gao, X.; Liu, S.; Liu, L.; et al. IL-37 inhibits the maturation of dendritic cells through the IL-1R8-TLR4-NF-kappaB pathway. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2019, 1864, 1338–1349. [Google Scholar] [CrossRef]
- Pan, Y.; Wen, X.; Hao, D.; Wang, Y.; Wang, L.; He, G.; Jiang, X. The role of IL-37 in skin and connective tissue diseases. Biomed. Pharmacother. 2020, 122, 109705. [Google Scholar] [CrossRef] [PubMed]
- Charrad, R.; Berraïes, A.; Hamdi, B.; Ammar, J.; Hamzaoui, K.; Hamzaoui, A. Anti-inflammatory activity of IL-37 in asthmatic children: Correlation with inflammatory cytokines TNF-alpha, IL-beta, IL-6 and IL-17A. Immunobiology 2016, 221, 182–187. [Google Scholar] [CrossRef]
- Gugliandolo, A.; Caraffa, A.L.; Gallenga, C.E.; Kritas, S.K.; Ronconi, G.; Trubiani, O.; Conti, P.; Di Emidio, P.; Mazzon, E. Mesenchymal stem cells and IL-37: A powerful combination. J. Biol. Regul. Homeost. Agents 2019, 33, 1019–1022. [Google Scholar]
- Tsilioni, I.; Patel, A.B.; Pantazopoulos, H.; Berretta, S.; Conti, P. IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin. Proc. Natl. Acad. Sci. USA 2019, 116, 21659–21665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Della Valle, L.; Gatta, A.; Farinelli, A.; Scarano, G.; Lumaca, A.; Tinari, N.; Cipollone, F.; Paganelli, R.; Di Gioacchino, M. Allergooncology: An expanding research area. J. Biol. Regul. Homeost. Agents 2020, 34, 319–326. [Google Scholar] [PubMed]
- Hahn, M.; Frey, S.; Hueber, A.J. The novel interleukin-1 cytokine family members in inflammatory diseases. Curr. Opin. Rheumatol. 2017, 29, 208–213. [Google Scholar] [CrossRef]
- Cavalli, G.; Dinarello, C.A. Suppression of inflammation and acquired immunity by IL-37. Immunol. Rev. 2018, 281, 179–190. [Google Scholar] [CrossRef] [PubMed]
- Cavalli, G.; Koenders, M.; Kalabokis, V.; Kim, J.; Tan, A.C.; Garlanda, C.; Mantovani, A.; Dagna, L.; Joosten, L.A.; Dinarello, C.A. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology 2016, 55, 2220–2229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Stored Enzymes |
Tryptase |
Chymase |
Cathepsin G |
Phospholipase |
Kininogenase |
Carboxypeptidase A |
Cholinesterase |
Stored Cytokine |
TNF |
De Novo Synthesized Cytokines |
Cytokines: IL-1, 2, 3, 5, 6, 7, 8, 9, 13, 16, 17, 33, and TNF |
Arachidonic Acid product: PGD2 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Conti, P.; Pregliasco, F.E.; Bellomo, R.G.; Gallenga, C.E.; Caraffa, A.; Kritas, S.K.; Lauritano, D.; Ronconi, G. Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra. Int. J. Mol. Sci. 2021, 22, 8076. https://doi.org/10.3390/ijms22158076
Conti P, Pregliasco FE, Bellomo RG, Gallenga CE, Caraffa A, Kritas SK, Lauritano D, Ronconi G. Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra. International Journal of Molecular Sciences. 2021; 22(15):8076. https://doi.org/10.3390/ijms22158076
Chicago/Turabian StyleConti, Pio, Fabrizio E. Pregliasco, Rosa G. Bellomo, Carla E. Gallenga, Alessandro Caraffa, Spyros K. Kritas, Dorina Lauritano, and Gianpaolo Ronconi. 2021. "Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra" International Journal of Molecular Sciences 22, no. 15: 8076. https://doi.org/10.3390/ijms22158076